T-lymphoblastic Lymphoma
13
5
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
15%
2 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (13)
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma